Overview
Primary malignant mesothelioma is a rare and aggressive neoplasm arising from the mesothelial cells lining serosal cavities, most commonly affecting the pleura but also potentially involving the pericardium 1.Diagnosis
Clinical Presentation: Often nonspecific, may include chest pain, dyspnea, and pericardial effusion 1.
Imaging: CT and MRI can show characteristic masses or effusions 1.
Diagnostic Imaging: Gallium-67 scintigraphy can highlight abnormal uptake indicative of mesothelioma, aiding in diagnosis 1.
Biopsy: Definitive diagnosis requires histopathological examination, often via pericardial biopsy 1.
Tumor Markers: Elevated levels of mesothelin and osteopontin may support diagnosis but are not definitive 1.Management
First-Line Treatment: Surgical resection (pericardiectomy) when feasible 1.
Adjuvant Therapy: Chemotherapy regimens such as pemetrexed and platinum-based agents are commonly used, though specific dosing details are not provided in the abstract 1.
Radiation Therapy: May be considered for palliation in unresectable cases 1.
Immunotherapy: Emerging role, but specific recommendations are not detailed in the provided abstract 1.Special Populations
Comorbidities: Presence of systemic sclerosis can complicate diagnosis and management, as seen in the case report 1.Key Recommendations
Utilize gallium-67 scintigraphy for detecting abnormal pericardial uptake suggestive of primary pericardial mesothelioma (Evidence: Weak) 1.
Confirm diagnosis through histopathological examination following imaging suspicion (Evidence: Weak) 1.
Consider surgical intervention (pericardiectomy) when possible for definitive treatment (Evidence: Expert opinion) 1.References
1 Nishikimi T, Ochi H, Hirota K, Ikuno Y, Oku H, Takeuchi K et al.. Primary pericardial mesothelioma detected by gallium-67 scintigraphy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1987. link